EUVIMEDEUVIMED entdecken
Crossref

Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab

Keisuke Hoshi, Hiroshi Kunikata, Naoko Aizawa, Masayuki Yasuda, Tatsu Okabe, Hiroki Takizawa, Toshiaki Abe, Toru Nakazawa

International Ophthalmology · 2023

DOI: 10.1007/s10792-023-02870-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, 2023. Verfasst von Keisuke Hoshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Uveitis, Macula Lutea, Wet Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: JST grants from JSPS KAKENHI Grants-in-Aid, JST grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate baseline characteristics associated with the incidence of intraocular inflammation (IOI) after the intravitreal injection of brolucizumab (IVBr) for the treatment of neovascular age-related macular degeneration (nAMD). METHODS: This retrospective study included 66 eyes of 62 consecutive patients with nAMD who received IVBr (18 eyes were treatment naïve and 48 eyes had switched from other anti-vascular endothelial growth factor [VEGF] therapy). Baseline clinical characteristics were compared in non-IOI and IOI groups. RESULTS: Although a dry macula was achieved at a high rate even 6 months after IVBr, IOI occurred in 8 of 66 eyes (12.1%; all had switched therapy) during the study period. Baseline characteristics including age, sex, nAMD type, lens status, visual acuity, central macular thickness, and a history of diabetes did not differ between the groups. The number of previous anti-VEGF injections before IVBr was greater in the IOI group (P = 0.004), and the ratio of patients with a laser flare-cell photometry (LFCP) value over 15 photon count per millisecond (pc/ms) was higher in the IOI group (P = 0.017). Multivariate logistic regression analysis showed that a greater number of previous anti-VEGF injections (odds ratio [OR]: 1.12, P = 0.006; area under the curve: 0.82, cut-off score: 14.0) and an LFCP value over 15 pc/ms (OR: 81.6, P = 0.031) were significantly associated with the incidence of IOI after IVBr. CONCLUSION: A number of previous anti-VEGF injections greater than 14 and an LFCP value more than 15 pc/ms might be useful predictors of the incidence of IOI after IVBr in eyes with nAMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UveitisMacula LuteaWet Macular DegenerationHumansIncidenceRetrospective StudiesInflammationIntravitreal InjectionsAngiogenesis InhibitorsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Age-related macular degenerationAnti-vascular endothelial growth factorBrolucizumabIntraocular inflammationLaser flare-cell photometry

Substanzen

Angiogenesis InhibitorsbrolucizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan.
  • Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. kunikata@oph.med.tohoku.ac.jp.
  • Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Sendai, Japan. kunikata@oph.med.tohoku.ac.jp.
  • Division of Clinical Cell Therapy Center for Advanced Medical Research and Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Ophthalmic Imaging and Information Analytics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Förderung

  • JST grants from JSPS KAKENHI Grants-in-Aid
  • JST grants

Zitieren

APA

Hoshi, K., Kunikata, H., Aizawa, N., Yasuda, M., Okabe, T., Takizawa, H., Abe, T., & Nakazawa, T. (2023). Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. International Ophthalmology. https://doi.org/10.1007/s10792-023-02870-4

Vancouver

Hoshi K, Kunikata H, Aizawa N, Yasuda M, Okabe T, Takizawa H, et al. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. International Ophthalmology. 2023. doi:10.1007/s10792-023-02870-4

BibTeX
@article{Hoshi2023,
  author = {Hoshi, Keisuke and Kunikata, Hiroshi and Aizawa, Naoko and Yasuda, Masayuki and Okabe, Tatsu and Takizawa, Hiroki and Abe, Toshiaki and Nakazawa, Toru},
  title = {Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab},
  journal = {International Ophthalmology},
  year = {2023},
  doi = {10.1007/s10792-023-02870-4}
}
Kostenlos starten →